---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-008409"
form_type: "8-K"
ticker: "LNSR"
cik: "0001320350"
company_name: "LENSAR, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T01:53:45.039229+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# LENSAR Q4 2021 revenue $11.2M (+35% YoY); full-year revenue up 31% to $34.2M; net loss narrows

## Summary
- Q4 revenue $11.2M vs $8.3M YoY; full-year revenue $34.2M (+31% vs 2020).
- Net loss $3.9M ($0.41 per share) vs $6.8M ($0.78) in Q4 2020; loss narrowed.
- Procedure volume up 37% in Q4 and 35% for full year 2021.
- ALLY Adaptive Cataract Treatment System 510(k) submitted and accepted for FDA substantive review.
- Cash of $31.6M with only $0.7M used in Q4; commercial launch of ALLY expected in 2022 subject to FDA clearance.

## SEC filing metadata
- accession: 0001564590-22-008409
- form_type: 8-K
- ticker: LNSR
- cik: 0001320350
- company_name: LENSAR, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/0001564590-22-008409-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1320350/000156459022008409/lnsr-8k_20220303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-008409
- JSON: https://secwatch.observer/filing/0001564590-22-008409.json
- Plain text: https://secwatch.observer/filing/0001564590-22-008409.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.